IRCT20190417043295N2.

Study name	Evaluation of the effect of ivermectin in intubated COVID‐19 patients
Methods	Trial design: double‐blind RCT with 2 parallel arms Type of record: trial register entry Sample size: 40 Setting: inpatient Country: Iran Language: English Number of centres: 1 Study purpose (treatment, prevention): treatment Trial registration number: IRCT20190417043295N2 Date of registration: 20 September 2021
Participants	Inclusion criteria Intubated patients on ICU COVID‐19 PCR test positive No increase in liver enzymes > 18 years old Exclusion criteria History of drug allergy Pregnant Women Patient's refusal to continue participating in the study
Interventions	Details of intervention Type and dose: Ivermectin, 6 mg twice daily on day 1 and 3 mg twice daily on day 2‐5 Route of administration: oral Treatment details of control group Placebo Concomitant therapy: standard of care (no details provided) administered in both study arms
Outcomes	Primary study outcome Mortality rate at 30 days Relevant review outcomes planned Mortality rate at 30 days Additional study outcomes Intubation period Lung Compliance
Starting date	23 September 2021
Contact information	Reza Baghbanian Assistant professor at Ahvaz University of Medical Sciences 24 metery street, east sahely highway, Ahvaz Khouzestan baghbanian.r@ajums.ac.ir shouman66@gmail.com
Notes	Recruitment status: recruiting Prospective completion date: January 2022 Planned completion date more than 6 months ago: no Date last update posted: 20 September 2021 Sponsor/funding: Ahvaz University of Medical Sciences